The Effect Of Metformin On Clinical And Metabolic Outcomes In Women With Polycystic Ovary Syndrome: A Systematic Review And Meta-Analysis
Abstract
Background: Polycystic ovary syndrome (PCOS) is a prevalent endocrine-metabolic disorder among women of reproductive age, characterized by hyperandrogenism, menstrual irregularity, and insulin resistance. Metformin, an insulin-sensitizing agent, is widely used to address metabolic, reproductive, and cardiovascular dysfunctions associated with PCOS. This systematic review and meta-analysis evaluated the clinical and metabolic effects of metformin across randomized controlled trials and comparative studies. Methods: Twelve peer-reviewed studies were systematically analyzed following PRISMA 2020 guidelines. Eligible studies included randomized trials and cohort studies examining the effects of metformin, alone or in combination with other interventions, on metabolic (BMI, insulin resistance, lipid profile) and reproductive (ovulation, menstrual regularity, androgen levels) outcomes in women with PCOS. Results: Metformin consistently improved fasting insulin, HOMA-IR, and serum testosterone levels, with moderate reductions in BMI and waist circumference. Combination regimens, such as metformin with semaglutide or oral contraceptives, yielded superior improvements in metabolic control and menstrual regularity. Cardiovascular risk markers and endothelial function also improved significantly. However, response variability across phenotypes was observed. Conclusions: Metformin demonstrates robust efficacy in enhancing metabolic and reproductive health in women with PCOS. Its…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.